U.S. markets closed

Bio-Path Holdings, Inc. (BPTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.1600+0.0700 (+1.71%)
At close: 04:00PM EDT
4.2400 +0.08 (+1.92%)
After hours: 05:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.0900
Bid4.1600 x 800
Ask4.2400 x 1200
Day's Range4.0600 - 4.2400
52 Week Range2.6800 - 8.6200
Avg. Volume35,227
Market Cap29.786M
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-1.6020
Earnings DateAug 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BPTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bio-Path Holdings, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • GlobeNewswire

    Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

    HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 16, 2022 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2022 and to provide a business overview. To access the live conferenc


    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq:BPTH)

    DALLAS, TX / ACCESSWIRE / June 13, 2022 / Bio-Path Holdings, Inc. (Nasdaq:BPTH) The full report can be accessed by clicking on the following link: http://stonegateinc.

  • GlobeNewswire

    Bio-Path Holdings Reports First Quarter 2022 Financial Results

    Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent corporate developments. “Throughout the first quarter, we continued to advance our missi